To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy

S. M. Yin; D. L. Li

doi:10.1016/j.stem.2024.10.009

To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy

S. M. Yin
, D. L. Li^*

^*此作品的通讯作者

生命科学学院

East China Normal University

科研成果: 期刊稿件 › 评论/辩论

2 引用（Scopus）

摘要

Epitope editing is a promising strategy for protecting hematopoietic cells from eradication by immunotherapies. Recently, in Cell Stem Cell, Ji et al. applied both base editing (BE) and prime editing (PE) to alter the epitope of CD123 in hematopoietic stem cells for CAR-T therapy against acute myeloid leukemia.¹

源语言	英语
页（从-至）	1557-1559
页数	3
期刊	Cell Stem Cell
卷	31
期	11
DOI	https://doi.org/10.1016/j.stem.2024.10.009
出版状态	已出版 - 7 11月 2024

访问文件

10.1016/j.stem.2024.10.009

其它文件与链接

链接到 Scopus 的出版物

引用此

@article{e951249bf3574807971547e560e8cb71,

title = "To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy",

abstract = "Epitope editing is a promising strategy for protecting hematopoietic cells from eradication by immunotherapies. Recently, in Cell Stem Cell, Ji et al. applied both base editing (BE) and prime editing (PE) to alter the epitope of CD123 in hematopoietic stem cells for CAR-T therapy against acute myeloid leukemia.1",

author = "Yin, \{S. M.\} and Li, \{D. L.\}",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Inc.",

year = "2024",

month = nov,

day = "7",

doi = "10.1016/j.stem.2024.10.009",

language = "英语",

volume = "31",

pages = "1557--1559",

journal = "Cell Stem Cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "11",

}

TY - JOUR

T1 - To BE or to PE

T2 - Prime editors provide more choices for epitope-editing-based immunotherapy

AU - Yin, S. M.

AU - Li, D. L.

PY - 2024/11/7

Y1 - 2024/11/7

N2 - Epitope editing is a promising strategy for protecting hematopoietic cells from eradication by immunotherapies. Recently, in Cell Stem Cell, Ji et al. applied both base editing (BE) and prime editing (PE) to alter the epitope of CD123 in hematopoietic stem cells for CAR-T therapy against acute myeloid leukemia.1

AB - Epitope editing is a promising strategy for protecting hematopoietic cells from eradication by immunotherapies. Recently, in Cell Stem Cell, Ji et al. applied both base editing (BE) and prime editing (PE) to alter the epitope of CD123 in hematopoietic stem cells for CAR-T therapy against acute myeloid leukemia.1

UR - https://www.scopus.com/pages/publications/85207806050

U2 - 10.1016/j.stem.2024.10.009

DO - 10.1016/j.stem.2024.10.009

M3 - 评论/辩论

C2 - 39515298

AN - SCOPUS:85207806050

SN - 1934-5909

VL - 31

SP - 1557

EP - 1559

JO - Cell Stem Cell

JF - Cell Stem Cell

IS - 11

ER -

To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy

摘要

访问文件

其它文件与链接

指纹

引用此